Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

Key Takeaways Vibegron treatment in men with OAB and BPH showed positive long-term safety and efficacy over 52 weeks. The extension trial involved 276 participants, with 90.6% completing the study.

Colin M. Goudelocke, MD, discusses the PEER trials, which are assessing the safety and efficacy of SNM lead sensing for optimizing SNM programming.

Howard B. Goldman, MD, FACS, discusses innovations such as tibial nerve stimulation devices, pudendal nerve targeting, and alternative stimulation frequencies.

Experts discuss the patient demographics and clinical trial design of the phase 2b SunRISe-1 study investigating the use of TAR-200 as a monotherapy and in combination with cetrelimab (a PD-1 ...

This bill would cut funds for research projects in disease states such as prostate cancer, bladder cancer, kidney cancer, and interstitial cystitis.

In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 4-5 in opposition of a favorable benefit-risk profile for UGN-102 (mitomycin) intravesical solution in adult patients with recurrent low-grade ...

Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

Cxbladder Triage test reduces cystoscopy and imaging in low-risk microscopic hematuria patients, optimizing diagnostic workflows. The study involved 3,353 patients, showing decreased cystoscopy and CT ...

A recent study examined the relationship between randomized controlled trials and real-world efficacy of prostate cancer treatments. 1 Investigators found that benefits of treatments that are observed ...

Combining reduced-dose olaparib with radium-223 improved rPFS in mCRPC patients, especially those without prior docetaxel and limited bone metastases. The combination's efficacy is based on mechanisms ...